Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NLNK genius vax developer, Dr. Monath, Now Chairman of GOVX @ .06, $3.2M cap
Link:
https://www.geovax.com/scientific-advisory-board.html
ROKA @ 4.45. Low vol dip. Nice op
CRTN: Strong 10-K due in 3 weeks. Catalyst event moves low floater higher.
CRTN looking very good indeed and the interest level will only get bigger, imo.
CEO is signaling an excellent 10-K for 2016.
In addition , a very strong 2017 is underway.
One of the big plays over next few weeks and a strong one all year.
Link:
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
CRTN: Strong 10-K due in 3 weeks. Catalyst event moves low floater higher.
CRTN looking very good indeed and the interest level will only get bigger, imo.
CEO is signaling an excellent 10-K for 2016.
In addition , a very strong 2017 is underway.
One of the big plays over next few weeks and a strong one all year.
Link:
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
GOVX: NIAD Zika vaccine funding.
NAID plans to devote $129M dollars to Zika vaccine research in 2017.
So far, not one dime has been doled out by NAID or anyone else.
GeoVax applied for a grant in April, 2016.
Almost a certainty that GOVX is due a payday.
GOVX: Interesting report that includes GeoVax
Link:
http://finance.yahoo.com/news/global-hiv-vaccine-market-clinical-171000368.html
CRTN: Moving big in coming sessions.
CRTN @ $1.18 Table pounding time. Monday starts countdown to 10-K. Three weeks,
The CRTN run-up to Nasdaq full compliance a few weeks back created real excitement.
Now the turnaround 10-K looms.
Imo, CRTN is going to run higher into that event.
Getting some shares today was and is the ticket, imo.
CRTN may be the cheapest Nasdaq company that is now turning a profit.
As that 10-K gets closer the interest level is going to spike and the share price with it, imo.
CRTN @ $1.18 Table pounding time. Monday starts countdown to 10-K. Three weeks,
The CRTN run-up to Nasdaq full compliance a few weeks back created real excitement.
Now the turnaround 10-K looms.
Imo, CRTN is going to run higher into that event.
Getting some shares today was and is the ticket, imo.
CRTN may be the cheapest Nasdaq company that is now turning a profit.
As that 10-K gets closer the interest level is going to spike and the share price with it, imo.
$CRTN @ $1.18:Tiny 6M float & the ONLY profitable Nasdaq company trading UNDER $4.00.....2017 EPS est .40 cents = $6.00+ stock price.
$CRTN @ $1.18: Tiny 6M float & the ONLY profitable Nasdaq company trading UNDER $4.00.....2017 EPS est .40 cents = $6.00+ stock price.
CRTN @ $1.17. Drumbeat for steller 2017 EPS starting. $6 soon
10-K for 2016 $ Q4 2016 out likely gets posted in a few weeks.
Imo, CRTN heats up nicely as that day draws near.
CRTN is set up to be one of the excellent plays for all of 2017.
Loading up down here is likely a multi-bag winner.
A 2017 EPS of .40 along with a 6M float makes CRTN a top Nasdaq play at todays price, imo.
Novemeber, 2016: Growth
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
January, 2017: Nasdaq full compliance:
http://finance.yahoo.com/news/cartesian-regains-compliance-nasdaq-minimum-130100827.html
Website:
http://www.cartesian.com/
CRTN @ $1.17. Drumbeat for steller 2017 EPS starting.
10-K for 2016 $ Q4 2016 out likely gets posted in a few weeks.
Imo, CRTN heats up nicely as that day draws near.
CRTN is set up to be one of the excellent plays for all of 2017.
Loading up down here is likely a multi-bag winner.
A 2017 EPS of .40 along with a 6M float makes CRTN a top Nasdaq play at todays price, imo.
Novemeber, 2016: Growth
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
January, 2017: Nasdaq full compliance:
http://finance.yahoo.com/news/cartesian-regains-compliance-nasdaq-minimum-130100827.html
Website:
http://www.cartesian.com/
GOVX: Fla hands out Zika Funds.
This is STATE money and is unrelated to the $485M Fed $$ that is yet to be doled out.
GOVX is in line for a nice payday on that.
The move by Gov. Scott to release funds from his budget will force the Feds to get their cash out there soon, so as not to precipitate another public relations disaster as the warmer months approach.
Expect GOVX to get a Zika Fed $$ payday soon.
NOTE: The Fed AIDS vax cash is entirely seperate, of course. Maybe Millions$$
Link: Fla Zika funds:
http://www.flgov.com/2016/09/22/gov-scott-authorizes-25-million-in-state-funds-for-zika-virus-vaccine-research-and-development/
ROKA @ $5.25....GOVX @ .065 cents. $3.2M market cap next...eom
GOVX: Steady buy action. Major Fed Zika Virus & AIDS vax $$ due,
ROKA @ $5...but the biggest bio play is yet to pop.
GOVX still under .07 with a $3.2M market cap.
GeoVax is the bio/pharma with the biggest bang for the buck in any market, imo.
I have been slamming some good ones but GOVX is the #1 play now, imo.
NOTE:1/30/2017 link:
Here is how the GOVX AIDS vaccine works.
https://eurekalert.org/pub_releases/2017-01/ehs-rds013117.php
Most of .06s gone. volume moves GOVX above .07. The 200DMA.
Elevated volume recently on many strong developments.
GOVX headed higher.
SNY & Tiny $GOVX @ .06, $3.2M market cap featured in Zika article.
Feb 1, 2017:
Link:
http://www.pharmavoice.com/article/2017-2-zika-research/
ROKA: Getting action over 50DMA
INO, Sanofi & tiny GOVX: Zika science leaders.Link
NOTE: This article discusses research by Sanofi, Inovio and GeoVax, (GOVX @ .06, Tiny $3.2M market cap) Great DD here.
PlasmaVoice: Feb.,2017
GeoVax’s approach to Zika vaccine development uses a recombinant Modified Vaccinia Ankara virus (MVA) viral vector to produce virus-like particles (VLPs) in the person being vaccinated. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating the immune system to recognize, prevent, and control the target infection.
In human clinical trials of the company’s HIV vaccines (which have completed Phase IIa trials), GeoVax has demonstrated that MVA-VLPs are safe and can elicit strong and durable antibody and cellular immune responses to fight HIV infections.
For the Zika virus (ZIKV), GeoVax is working in collaborations with the University of Georgia Research Foundation and the Centers for Disease Control.
With the CDC, the company has developed an animal model and has performed mouse efficacy studies. ZIKV and reagents will be supplied by the University of Texas Medical Branch.
MVA has been safely administered to 120,000 humans in Germany in a campaign for eradication of smallpox in the 60s and later as a vector for delivery of other vaccines including HIV, malaria and tuberculosis, says Farshad Guirakhoo, Ph.D., chief scientific officer of GeoVax.
“Our Zika vaccine has shown 100% protection against death in a mouse model after a single inoculation,” he says. “MVA has been adapted to replicate in chickens, so when it is used in humans as a vector for delivery of other vaccine target antigens, the virus can’t reproduce infectious progeny to spread in the host, making it highly safe for people.”
Unlike other companies that are using viruses to create a Zika vaccine, Inovio is developing a DNA-based monoclonal antibody. This DNA-based monoclonal antibody technology has the potential to lead to products that can be designed and manufactured on a large scale using common fermentation technology. Inovio’s DNA-based immunotherapy platform can target both immediate therapy through delivery of dMAb products as well as long-term immunity via DNA vaccination.
Link:
http://www.pharmavoice.com/article/2017-2-zika-research/
GOVX: News. GeoVax update featured in PharmaVoice.
NOTE: This article discusses research by Sanofi, Inovio and GeoVax. Being placed in that tier is big, imo.
PlasmaVoice:Feb.,2017
GeoVax’s approach to Zika vaccine development uses a recombinant Modified Vaccinia Ankara virus (MVA) viral vector to produce virus-like particles (VLPs) in the person being vaccinated. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating the immune system to recognize, prevent, and control the target infection.
In human clinical trials of the company’s HIV vaccines (which have completed Phase IIa trials), GeoVax has demonstrated that MVA-VLPs are safe and can elicit strong and durable antibody and cellular immune responses to fight HIV infections.
For the Zika virus (ZIKV), GeoVax is working in collaborations with the University of Georgia Research Foundation and the Centers for Disease Control.
With the CDC, the company has developed an animal model and has performed mouse efficacy studies. ZIKV and reagents will be supplied by the University of Texas Medical Branch.
MVA has been safely administered to 120,000 humans in Germany in a campaign for eradication of smallpox in the 60s and later as a vector for delivery of other vaccines including HIV, malaria and tuberculosis, says Farshad Guirakhoo, Ph.D., chief scientific officer of GeoVax.
“Our Zika vaccine has shown 100% protection against death in a mouse model after a single inoculation,” he says. “MVA has been adapted to replicate in chickens, so when it is used in humans as a vector for delivery of other vaccine target antigens, the virus can’t reproduce infectious progeny to spread in the host, making it highly safe for people.”
Unlike other companies that are using viruses to create a Zika vaccine, Inovio is developing a DNA-based monoclonal antibody. This DNA-based monoclonal antibody technology has the potential to lead to products that can be designed and manufactured on a large scale using common fermentation technology. Inovio’s DNA-based immunotherapy platform can target both immediate therapy through delivery of dMAb products as well as long-term immunity via DNA vaccination.
Link:
http://www.pharmavoice.com/article/2017-2-zika-research/
GOVX: News.
PlasmaVoice:Feb.,2017
GeoVax’s approach to Zika vaccine development uses a recombinant Modified Vaccinia Ankara virus (MVA) viral vector to produce virus-like particles (VLPs) in the person being vaccinated. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating the immune system to recognize, prevent, and control the target infection.
In human clinical trials of the company’s HIV vaccines (which have completed Phase IIa trials), GeoVax has demonstrated that MVA-VLPs are safe and can elicit strong and durable antibody and cellular immune responses to fight HIV infections.
For the Zika virus (ZIKV), GeoVax is working in collaborations with the University of Georgia Research Foundation and the Centers for Disease Control.
With the CDC, the company has developed an animal model and has performed mouse efficacy studies. ZIKV and reagents will be supplied by the University of Texas Medical Branch.
MVA has been safely administered to 120,000 humans in Germany in a campaign for eradication of smallpox in the 60s and later as a vector for delivery of other vaccines including HIV, malaria and tuberculosis, says Farshad Guirakhoo, Ph.D., chief scientific officer of GeoVax.
“Our Zika vaccine has shown 100% protection against death in a mouse model after a single inoculation,” he says. “MVA has been adapted to replicate in chickens, so when it is used in humans as a vector for delivery of other vaccine target antigens, the virus can’t reproduce infectious progeny to spread in the host, making it highly safe for people.”
Unlike other companies that are using viruses to create a Zika vaccine, Inovio is developing a DNA-based monoclonal antibody. This DNA-based monoclonal antibody technology has the potential to lead to products that can be designed and manufactured on a large scale using common fermentation technology. Inovio’s DNA-based immunotherapy platform can target both immediate therapy through delivery of dMAb products as well as long-term immunity via DNA vaccination.
LINK
http://www.pharmavoice.com/article/2017-2-zika-research/
GOVX: Emory University owns 9.4%...Sabby Investment 5%.
GeoVax was an Emory University incubator company when it was formed.
ROKA @ $4.60. Has $17.86 a share & 1.6M micro-float.
Trading OVER 50DMA in the last 30 minutes.
Explosive move on tap
ROKA @ $4.60. Has $17.86 a share & 1.6M micro-float.
Trading OVER 50DMA in the last 30 minutes.
Explosive move on tap
ROKA @ $4.70s....Volume surge on tap?
GOVX: NLNKs Chief Science Officer also GOVX Chief Science Advisor., Elite name in vaccines.
Dr. Thomas Monath is one of the major names in vaccine science.
He developed the sensational 100% effective Ebola vaccine that made so much news in last few weeks. He did id while working for NLNK in partnership licensing deal with global giant Merck.
GOVX watchers are starting to make that connection now.
Stock has been on steady incremental move north in last two weeks.
Ready to break out about 200DMA 0f .07.
GOVX has 49M float. Sick.
GOVX: Thin above .07. MMs want to move GOVX above 200DMA.
Add some volume and it will pop, imo.
Red hot $NLNK & $MRK linked to $GOVX @ .07, $3.2M market cap.
Genius vax developer, Dr.T Monath, is tha Chief Science Officer for $NLNK and the Chairman of the GoeVax Science Advisory Board.
Dr. Thomas Monath, NLNK Chief Science Officer & GOVX Science Advisory Board Chairman.
Dr. Thomas Monath: Developed the 100% effective Ebola vax for NLNK in partnership with Merck. NLNK is heating up nicely since that news hit a few weeks ago. Scroll down link for Dr. Monath bio.
http://www.newlinkgenetics.com/about-us/management/.
Dr. Thomas Monath recently became Chairman of the GeoVax Science Advisory Board. The Board is a whos who of vaccine science. Take a look at the names & resumes. Investors are slowly starting to take notice of tiny GeoVax.
https://www.geovax.com/news-events/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html
NOTE: Bio/pharma investors that know the vaccine sector know these Science Advisory Board member names. One more brick in the wall for GeoVax in regard to industry and investor respect. GeoVax stakeholders are sitting in the catbird seat right now.
Dr. Thomas Monath, NLNK Chief Science Officer & GOVX Science Advisory Board Chairman.
Dr. Thomas Monath: Developed the 100% effective Ebola vax for NLNK in partnership with Merck. NLNK is heating up nicely since that news hit a few weeks ago. Scroll down link for Dr. Monath bio.
http://www.newlinkgenetics.com/about-us/management/.
Dr. Thomas Monath recently became Chairman of the GeoVax Science Advisory Board. The Board is a whos who of vaccine science. Take a look at the names & resumes. Investors are slowly starting to take notice of tiny GeoVax.
https://www.geovax.com/news-events/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html
NOTE: Bio/pharma investors that know the vaccine sector know these Science Advisory Board member names. One more brick in the wall for GeoVax in regard to industry and investor respect. GeoVax stakeholders are sitting in the catbird seat right now.
GOVX @ .07: GeoVax volume increasing on no news.
Most trades today were on the ask right at or near the 200DMA.
Feels very comfortable to be holding GOVX here.
GeoVax: Twitter.
https://twitter.com/geovax_news?lang=en
GOVX: Volume increasing on no news.
Most trades today were on the ask right at or near the 200DMA.
Feels very comfortable to be holding GOVX here.
GeoVax: Twitter.
https://twitter.com/geovax_news?lang=en
ROKA @ $4.65. Right above tech high.
Micro-floater powering up, imo.
GOVX: Fed AIDS vax milestone payment due.
Link: Human vaccinations begin:
https://www.geovax.com/component/easyblog/entry/2017/01/23/geovax-announces-initiation-of-hiv-human-clinical-trial.html?Itemid=101
$7.8M Fed $$ grant for AIDS vax program:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
NOTE: GeoVax market cap is $3.3M. The grant dollars may be quite large in relation to the total market cap.
GOVX: Fed AIDS vax milestone payment due.
Link: Next round of human vaccinations begin:
https://www.geovax.com/component/easyblog/entry/2017/01/23/geovax-announces-initiation-of-hiv-human-clinical-trial.html?Itemid=101
$7.8M Fed $$ grant for AIDS vax program:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
NOTE: GeoVax market cap is $3.3M. The grant dollars may be quite large in relation to the total market cap.
GOVX @ .06. Market cap $3.3M. Due $2xs that in Fed $$ milestone grants.
GOVX is due a milestone payment on a $7.8M grant awarded them in June, 2016 for AIDS vax.
The Fed Zika funding passed by Congress in November, 2016 is also OVERDUE for pay out to GOVX and others.
Nice spot to be in.
$7.8M Fed $$ grant. Milestone due:
NOTE: The grant is TWICE the company market cap:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
GOVX @ .06: Fed $$ due for Zika Virus & AIDS prevention vaccine. At any time.
GOVX is due a milestone payment on a $7.8M grant awarded them in June, 2016 for AIDS vax.
The Fed Zika funding passed by Congress in November, 2016 is also OVERDUE for pay out to GOVX and others.
Nice spot to be in.
$7.8M Fed $$ grant. Milestone due:
NOTE: The grant is TWICE the company market cap:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
GOVX @ .06: Fed $$ due for Zika Virus & AIDS prevention vaccine. At any time.
GOVX is due a milestone payment on a $7.8M grant awarded them in June, 2016 for AIDS vax.
The Fed Zika funding passed by Congress in November, 2016 is also OVERDUE for pay out to GOVX and others.
Nice spot to be in.
$7.8M Fed $$ grant. Milestone due:
NOTE: The grant is TWICE the company market cap:
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html